EX-10.14



 Exhibit 10.14 
 INDEMNIFICATION AGREEMENT 
 THIS INDEMNIFICATION AGREEMENT (this
“Agreement”), dated as of                  , is made by and between Mallinckrodt Brand Pharmaceuticals, Inc., a Delaware corporation (“Brand
Pharma”), and                  (“Indemnitee”). 
 WHEREAS, Brand Pharma is a wholly owned subsidiary of Mallinckrodt plc; 
 WHEREAS,
it is essential to Brand Pharma and Mallinckrodt plc that Mallinckrodt plc retain and attract as directors and secretary the most capable persons available; 
 WHEREAS, Brand Pharma has requested that the Indemnitee serve as a director, officer, secretary or employee of Mallinckrodt plc, and, if requested to do so by Brand Pharma, as a director, officer,
secretary, employee, trustee, agent, or fiduciary of another foreign or domestic corporation, partnership, limited liability company, joint venture, employee benefit plan, trust, or other Enterprise; and 

WHEREAS, each of Mallinckrodt plc, Brand Pharma and Indemnitee recognize the increased risk of litigation and other claims currently
being asserted against directors and officers of companies; 
 WHEREAS, due to restrictions imposed by Irish law, the Articles
of Association of Mallinckrodt plc do not confer indemnification and advancement rights on its directors and secretary as broad as the indemnification and advancement rights that are customarily provided to the directors and secretary of a company
organized under the laws of a U.S. state; 
 WHEREAS, in recognition of Indemnitee’s need for (i) substantial
protection against personal liability, (ii) specific contractual assurance that such protection will be available to Indemnitee (regardless of, among other things, any amendment to or revocation of Mallinckrodt plc’s Articles of
Association, the certificate of incorporation or bylaws of Brand Pharma (the “Brand Pharma Organizational Documents”) or any change in the composition of Mallinckrodt plc’s Board of Directors or acquisition transaction relating to
Mallinckrodt plc), Brand Pharma wishes to provide in this Agreement for the indemnification by Brand Pharma of and the advancing by Brand Pharma of expenses to Indemnitee as set forth in this Agreement; 

NOW, THEREFORE, in consideration of the above premises and of Indemnitee continuing to serve Mallinckrodt plc directly or, at Brand
Pharma’s request, with another Enterprise, and intending to be legally bound hereby, the parties agree as follows: 
 1. Certain
Definitions. 
 (a) Affiliate: any corporation or other person or entity that directly, or indirectly through one or more
intermediaries, controls or is controlled by, or is under common control with, the person specified. 
 (b) Board: the Board of Directors
of Mallinckrodt plc. 







 (c) Change in Control: shall be deemed to have occurred if: 

(i) any “person,” as such term is used in Sections 3(a)(9) and 13(d) of the Exchange Act, becomes a “beneficial
owner,” as such term is used in Rule 13d-3 promulgated under the Exchange Act, of 50% or more of the Voting Shares (as defined below) of Mallinckrodt plc; 
 (ii) the majority of the Board consists of individuals other than Incumbent Directors, which term means the members of the Board as of the execution hereof, provided that any person becoming a director
subsequent to such time whose election or nomination for election was supported by three-quarters of the directors who immediately prior to such election or nomination for election comprised the Incumbent Directors shall be considered to be an
Incumbent Director; 
 (iii) Mallinckrodt plc adopts any plan of liquidation providing for the distribution of all or
substantially all of its assets; 
 (iv) all or substantially all of the assets or business of Mallinckrodt plc is disposed of
pursuant to a merger, consolidation or other transaction (unless the shareholders of Mallinckrodt plc immediately prior to such a merger, consolidation or other transaction beneficially own, directly or indirectly, in substantially the same
proportion as they owned the Voting Shares of Mallinckrodt plc, all of the Voting Shares or other ownership interests of the entity or entities, if any, that succeed to the business of Mallinckrodt plc); or 

(v) Mallinckrodt plc combines with another company and is the surviving entity but, immediately after the combination, the shareholders
of Mallinckrodt plc immediately prior to the combination hold, directly or indirectly, 50% or less of the Voting Shares of the combined company (there being excluded from the number of shares held by such shareholders, but not from the Voting Shares
of the combined company, any shares received by Affiliates of such other company in exchange for shares of such other company), provided, however, that any occurrence that would, in the absence of this proviso, otherwise constitute a Change in
Control pursuant to any of clause (i), (iii), (iv) or (v) above, shall not constitute a Change in Control if such occurrence is approved by a majority of the directors on the Board who were directors immediately prior to such occurrence.

 (d) Enterprise: Mallinckrodt plc and any other corporation, limited liability company, partnership, joint venture, trust, employee
benefit plan or other enterprise of which Indemnitee is or was serving at the request of Brand Pharma as a director, officer, secretary, trustee, general partner, managing member, fiduciary, board of directors’ committee member, employee or
agent. 
 (e) Exchange Act: the U.S. Securities Exchange Act of 1934, as amended. 

(f) Expenses: any expense, liability, or loss, including attorneys’ fees, judgments, fines, ERISA excise taxes and penalties, amounts paid or
to be paid in settlement, any interest, assessments, or other charges imposed thereon, any federal, state, local, or foreign taxes imposed as a result of the actual or deemed receipt of any payments under this Agreement, and all other costs and
obligations, paid or incurred in connection with investigating, defending, prosecuting (subject to Section 2(b)), being a witness in, participating in (including on appeal), or preparing for any of the foregoing in, any Proceeding relating to
any Indemnifiable Event. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond,
or other appeal bond or its equivalent. 

  
 - 2 -









 (g) Indemnifiable Event: any event or occurrence that takes place either prior to or after the
execution of this Agreement, related to the fact that Indemnitee is or was a director, officer, secretary or employee of Mallinckrodt plc, or while a director or secretary of Mallinckrodt plc is or was serving at the request of Brand Pharma as a
director, officer, secretary, employee, trustee, agent, or fiduciary of another foreign or domestic corporation, partnership, limited liability company, joint venture, employee benefit plan, trust, or other Enterprise, or related to anything done or
not done by Indemnitee in any such capacity, whether or not the basis of the Proceeding is alleged action in an official capacity as a director, officer, secretary, employee, trustee, agent, or fiduciary or in any other capacity while serving as a
director, officer, secretary, employee, trustee, agent, or fiduciary. 
 (h) Independent Counsel: the meaning specified in
Section 3. 
 (i) Proceeding: any threatened, pending, or completed action, suit, or proceeding or any alternative dispute
resolution mechanism (including an action by or in the right of Mallinckrodt plc), or any inquiry, hearing, or investigation, whether conducted by Mallinckrodt plc or any other party, that Indemnitee in good faith believes might lead to the
institution of any such action, suit, or proceeding, whether civil, criminal, administrative, investigative, or other. 
 (j) Reviewing
Party: the meaning specified in Section 3. 
 (k) Voting Shares: shares of any class or classes having general voting power
under ordinary circumstances, in the absence of contingencies, to elect the directors (or similar function) of an Enterprise. 
 2. Agreement
to Indemnify. 
 (a) General Agreement. In the event Indemnitee was, is, or becomes a party to or witness or other participant in, or
is threatened to be made a party to or witness or other participant in, a Proceeding by reason of (or arising in part out of) an Indemnifiable Event, Brand Pharma shall indemnify Indemnitee from and against any and all Expenses to the fullest extent
permitted by law, as the same exists or may hereafter be amended or interpreted (but in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation permits Brand Pharma to provide broader
indemnification rights than were permitted prior thereto). The parties hereto intend that this Agreement shall provide for indemnification in excess of that expressly permitted by statute or provided by Mallinckrodt plc’s Articles of
Association, the separate deed of indemnification which Indemnitee has with Mallinckrodt plc, the Brand Pharma Organizational Documents or applicable law. 
 (b) Initiation of Proceeding. Notwithstanding anything in this Agreement to the contrary, Indemnitee shall not be entitled to indemnification pursuant to this Agreement in connection with any
Proceeding initiated by Indemnitee against Mallinckrodt plc or any of its subsidiaries or any director, officer or employee of Mallinckrodt plc or any of its subsidiaries unless (i) Mallinckrodt plc has joined in or the Board has consented to
the initiation of such Proceeding; (ii) the Proceeding is one to enforce indemnification rights under Section 4; or (iii) the Proceeding is instituted after a Change in Control and Independent Counsel has approved its initiation.


  
 - 3 -









 (c) Expense Advances. If so requested by Indemnitee, Brand Pharma shall advance (within five business
days of such request) any and all Expenses to Indemnitee (an “Expense Advance”); provided that, (i) such Expense Advance shall be made only upon delivery to Brand Pharma of an undertaking by or on behalf of the Indemnitee to repay the
amount thereof if it is ultimately determined that Indemnitee is not entitled to be indemnified by Brand Pharma, (ii) Brand Pharma shall not (unless a court of competent jurisdiction shall determine otherwise) be required to make an Expense
Advance if and to the extent that the Reviewing Party has determined that Indemnitee is not permitted to be indemnified under applicable law, and (iii) if and to the extent that the Reviewing Party determines after payment of one or more
Expense Advances that Indemnitee would not be permitted to be so indemnified under applicable law, Brand Pharma shall be entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse Brand Pharma) for all such amounts theretofore paid. If
Indemnitee has commenced or commences legal proceedings in a court of competent jurisdiction or commences arbitration to secure a determination that Indemnitee is entitled to indemnification or Expense Advance, as provided in Section 4, any
determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law shall not be binding, and Indemnitee shall not be required to reimburse Brand Pharma for any Expense Advance until a final
determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or have lapsed). Indemnitee’s obligation to reimburse Brand Pharma for Expense Advances shall be unsecured and no interest shall be
charged thereon. 
 (d) Mandatory Indemnification. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee
has been successful on the merits or otherwise in defense of any Proceeding relating in whole or in part to an Indemnifiable Event or in defense of any issue or matter therein, Indemnitee shall be indemnified by Brand Pharma hereunder against all
Expenses incurred in connection therewith. 
 (e) Partial Indemnification. If Indemnitee is entitled under any provision of this
Agreement to indemnification by Brand Pharma for some or a portion of Expenses, but not, however, for the total amount thereof, Brand Pharma shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. 

(f) Prohibited Indemnification. No indemnification pursuant to this Agreement shall be paid by Brand Pharma: 

(i) on account of any Proceeding in which a final and non-appealable judgment is rendered against Indemnitee for an accounting of profits
made from the purchase or sale by Indemnitee of securities of Mallinckrodt plc pursuant to the provisions of Section 16(b) of the Exchange Act or similar provisions of any federal, state, or local laws; 

(ii) if a court of competent jurisdiction by a final and non-appealable judgment, shall determine that such indemnification is not
permitted under applicable law; 

  
 - 4 -









 (iii) on account of any Proceeding relating to an Indemnifiable Event as to which the
Indemnitee has been convicted of a crime constituting a felony under the laws of the jurisdiction where the criminal action had been brought (or, where a jurisdiction does not classify any crime as a felony, a crime for which Indemnitee is sentenced
to death or imprisonment for a term exceeding one year); or 
 (iv) on account of any Proceeding brought by Mallinckrodt plc or
any of its subsidiaries against Indemnitee. 
 3. Reviewing Party; Exhaustion of Remedies.

(a) Prior to any Change in Control, the reviewing party (the “Reviewing Party”) shall be any appropriate person or body consisting of a member
or members of the Board or any other person or body appointed by the Board who is not a party to the particular Proceeding with respect to which Indemnitee is seeking indemnification; after a Change in Control, the Independent Counsel referred to
below shall become the Reviewing Party. With respect to all matters arising after a Change in Control concerning the rights of Indemnitee to indemnity payments and Expense Advances under this Agreement, the separate deed of indemnification which
Indemnitee has with Mallinckrodt plc or any other agreement to which Mallinckrodt plc or any of its Affiliates is a party or under applicable law, Mallinckrodt plc’s Articles of Association or the Brand Pharma Organizational Documents now or
hereafter in effect relating to indemnification for Indemnifiable Events, Mallinckrodt plc and Brand Pharma shall seek legal advice only from independent counsel (“Independent Counsel”) selected by Indemnitee and approved by Mallinckrodt
plc (which approval shall not be unreasonably withheld), and who has not otherwise performed services for Mallinckrodt plc, Brand Pharma or the Indemnitee (other than in connection with indemnification matters) within the last five years. The
Independent Counsel shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing Mallinckrodt plc, Brand Pharma or Indemnitee in an action to determine
Indemnitee’s rights under this Agreement. Such counsel, among other things, shall render its written opinion to Mallinckrodt plc, Brand Pharma and Indemnitee as to whether and to what extent the Indemnitee should be permitted to be indemnified
under applicable law. In doing so, the Independent Counsel may consult with (and rely upon) counsel in any appropriate jurisdiction who would qualify as Independent Counsel (“Local Counsel”). Brand Pharma agrees to pay the reasonable fees
of the Independent Counsel and the Local Counsel and to indemnify fully such counsel against any and all expenses (including attorneys’ fees), claims, liabilities, loss, and damages arising out of or relating to this Agreement or the engagement
of Independent Counsel or the Local Counsel pursuant hereto. 
 (b) Prior to making written demand on Brand Pharma for indemnification pursuant
to Section 4(a) or making a request for Expense Advance pursuant to Section 2(c), Indemnitee shall (i) seek such indemnification or Expense Advance, as applicable, under any applicable insurance policy and (ii) request that
Mallinckrodt plc consider in its discretion whether to make such indemnification or Expense Advance, as applicable. Upon any such request by Indemnitee of Mallinckrodt plc, Mallinckrodt plc shall consider whether to make such indemnification or
Expense Advance, as applicable, based on the facts and circumstances related to the request. Mallinckrodt plc may require, as a condition to making any indemnification or Expense Advance, as applicable, that Indemnitee enter into an agreement
providing for such indemnification or Expense 

  
 - 5 -









 
Advance, as applicable, to be made subject to substantially the same terms and conditions applicable to an indemnification or Expense Advance, as applicable, by Brand Pharma hereunder (including,
without limitation, conditioning any Expense Advance upon delivery to Mallinckrodt plc of an undertaking of the type described in clause (i) of the proviso to Section 2(c)). In the event indemnification or Expense Advance, as applicable,
is not received pursuant to an insurance policy, or from Mallinckrodt plc, within 5 business days of the later of Indemnitee’s request of the insurer and Indemnitee’s request of Mallinckrodt plc as provided in the first sentence of this
Section 3(b), Indemnitee may make written demand on Brand Pharma for indemnification pursuant to Section 4(a) or make a request for Expense Advance pursuant to Section 2(c), as applicable. 

4. Indemnification Process and Appeal. 

(a) Indemnification Payment. Indemnitee shall be entitled to indemnification of Expenses, and shall receive payment thereof, from Brand Pharma in
accordance with this Agreement as soon as practicable after Indemnitee has made written demand on Brand Pharma for indemnification, unless the Reviewing Party has given a written opinion to Brand Pharma that Indemnitee is not entitled to
indemnification under applicable law. 
 (b) Adjudication or Arbitration. (i) Regardless of any action by the Reviewing Party, if
Indemnitee has not received full indemnification or Expense Advance to which Indemnitee is entitled hereunder within thirty days after making a demand or request in accordance with Section 4(a) or Section 2(c), as applicable (a
“Nonpayment”), Indemnitee shall have the right to enforce its indemnification rights under this Agreement by commencing litigation in any federal or state court located in the State of Delaware (a “Delaware Court”) having subject
matter jurisdiction thereof seeking an initial determination by the court or by challenging any determination by the Reviewing Party or any aspect thereof. Any determination by the Reviewing Party not challenged by Indemnitee in any such litigation
shall be binding on Mallinckrodt plc, Brand Pharma and Indemnitee. The remedy provided for in this Section 4 shall be in addition to any other remedies available to Indemnitee at law or in equity. Mallinckrodt plc, Brand Pharma and Indemnitee
hereby irrevocably and unconditionally (A) consent to submit to the non-exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (B) waive any objection to
the laying of venue of any such action or proceeding in the Delaware Court, and (C) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or
inconvenient forum. For the avoidance of doubt, nothing in this Agreement shall limit any right Indemnitee may have under applicable law to bring any action or proceeding in any other court. 

(ii) Alternatively, in the case of a Nonpayment, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a
single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. 
 (iii) In the event
that a determination shall have been made pursuant to Section 4(a) or 2(c) of this Agreement that Indemnitee is not entitled to indemnification or Expense Advance, any judicial proceeding or arbitration commenced pursuant to this
Section 4(b) shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced


  
 - 6 -









 
pursuant to this Section 4(b) Brand Pharma shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be. If Indemnitee
commences a judicial proceeding or arbitration pursuant to this Section 4(b), Indemnitee shall not be required to reimburse Brand Pharma for any advances pursuant to Section 2(c) until a final determination is made with respect to
Indemnitee’s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed). 
 (iv) In
the event that Indemnitee, pursuant to this Section 4(b), seeks a judicial adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of, this Agreement, and it is determined in said judicial
adjudication or arbitration that Indemnitee is entitled to receive all of the indemnification or advancement of Expenses sought, Indemnitee shall be entitled to recover from Brand Pharma, and shall be indemnified by Brand Pharma against, any and all
Expenses actually and reasonably incurred by him in such judicial adjudication or arbitration. If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive part but not all of the indemnification or
advancement of Expenses sought, the Indemnitee shall be entitled to recover from Brand Pharma, and shall be indemnified by Brand Pharma against, any and all Expenses reasonably incurred by Indemnitee in connection with such judicial adjudication or
arbitration. 
 (c) Defense to Indemnification, Burden of Proof, and Presumptions. (i) It shall be a defense to any action brought
by Indemnitee against Brand Pharma to enforce this Agreement that it is not permissible under applicable law for Brand Pharma to indemnify Indemnitee for the amount claimed. 
 (ii) In connection with any action or any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified hereunder, the burden of proving such a defense or
determination shall be on Brand Pharma. 
 (iii) Neither the failure of the Reviewing Party to have made a determination prior
to the commencement of such action by Indemnitee that indemnification of the Indemnitee is proper under the circumstances because Indemnitee has met the standard of conduct set forth in applicable law, nor an actual determination by the Reviewing
Party that the Indemnitee had not met such applicable standard of conduct, shall, of itself, be a defense to the action or create a presumption that the Indemnitee has not met the applicable standard of conduct. 

(iv) For purposes of this Agreement, to the fullest extent permitted by law, the termination of any claim, action, suit, or proceeding,
by judgment, order, settlement (whether with or without court approval), conviction, or upon a plea of nolo contendere, or its equivalent, shall not, of itself, create a presumption that Indemnitee did not meet any particular standard of conduct or
have any particular belief or that a court has determined that indemnification is not permitted by applicable law. 
 (v) For
purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of any Enterprise, including financial statements, or on information supplied
to Indemnitee by the management of such Enterprise in the course of their duties, or on the advice of legal counsel for such Enterprise or on information or records given or reports made to such Enterprise by an


  
 - 7 -









 
independent certified public accountant or by an appraiser or other expert selected by such Enterprise. The provisions of this Section 4(c)(v) shall not be deemed to be exclusive or to limit
in any way the other circumstances in which Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in applicable law. 
 (vi) The knowledge and/or actions, or failure to act, of any other director, trustee, partner, managing member, fiduciary, officer, agent or employee of any Enterprise shall not be imputed to Indemnitee
for purposes of determining any right to indemnification under this Agreement. 
 (vii) Brand Pharma shall be precluded from
asserting in any judicial proceeding or arbitration commenced pursuant to this Agreement that the procedures or presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any court or before any arbitrator that
Brand Pharma is bound by all the provisions of this Agreement. 
 5. Indemnification for Expenses Incurred in Enforcing Rights. In
addition to Indemnitee’s rights under Section 4(b)(iv), Brand Pharma shall indemnify Indemnitee against any and all Expenses that are incurred by Indemnitee in connection with any action brought by Indemnitee: 

(a) for indemnification or advance payment of Expenses under any agreement to which Brand Pharma or any of its Affiliates is a party (other than this
Agreement) or under applicable law, Mallinckrodt plc’s Articles of Association or the Brand Pharma Organizational Documents now or hereafter in effect relating to indemnification or advance payment of Expenses for Indemnifiable Events (it being
specified, for the avoidance of doubt, that this clause (a) shall not be deemed to provide Indemnitee with a right to the indemnification or advance payment of Expenses being sought in such action), and/or 

(b) for recovery under directors’ and officers’ liability insurance policies maintained by Mallinckrodt plc, 

but, in either case, only in the event that Indemnitee ultimately is determined to be entitled to such indemnification or expense advance or insurance
recovery, as the case may be. In addition, Brand Pharma shall, if so requested by Indemnitee, advance the foregoing Expenses and any Expenses incurred in any action brought pursuant to Section 4 to Indemnitee, subject to and in accordance with
Section 2(c). 
 6. Notification and Defense of Proceeding. 
 (a) Notice. Promptly after receipt by Indemnitee of notice of the commencement of any Proceeding, Indemnitee shall, if a claim in respect thereof is to be made against Brand Pharma under this
Agreement, notify Mallinckrodt plc and Brand Pharma of the commencement thereof; but the omission so to notify Mallinckrodt plc and Brand Pharma will not relieve Brand Pharma from any liability that it may have to Indemnitee, except as provided in
Section 6(c). 
 (b) Defense. With respect to any Proceeding as to which Indemnitee notifies Mallinckrodt plc and Brand Pharma of
the commencement thereof, Brand Pharma will be entitled to participate in the Proceeding at its own expense and except as otherwise provided below, to the extent Brand Pharma so wishes, it may assume the defense thereof with counsel reasonably
satisfactory to Indemnitee. After notice from Brand Pharma to Indemnitee of its election to assume the defense of 

  
 - 8 -









 
any Proceeding, Brand Pharma shall not be liable to Indemnitee under this Agreement or otherwise for any Expenses subsequently incurred by Indemnitee in connection with the defense of such
Proceeding other than reasonable costs of investigation or as otherwise provided below. Indemnitee shall have the right to employ legal counsel in such Proceeding, but all Expenses related thereto incurred after notice from Brand Pharma of its
assumption of the defense shall be at Indemnitee’s expense unless: (i) the employment of legal counsel by Indemnitee has been authorized by Brand Pharma, (ii) Indemnitee has reasonably determined that there may be a conflict of
interest between Indemnitee and Brand Pharma in the defense of the Proceeding, (iii) after a Change in Control, the employment of counsel by Indemnitee has been approved by the Independent Counsel, or (iv) Brand Pharma shall not in fact
have employed counsel to assume the defense of such Proceeding, in each of which cases all Expenses of the Proceeding shall be borne by Brand Pharma. Brand Pharma shall not be entitled to assume the defense of any Proceeding (x) brought by or
on behalf of Mallinckrodt plc or Brand Pharma, (y) as to which Indemnitee shall have made the determination provided for in (ii) above or (z) after a Change in Control (it being specified, for the avoidance of doubt, that Brand Pharma
may assume defense of any such proceeding described in this sentence with Indemnitee’s consent, provided that any such consent shall not affect the rights of Indemnitee under the foregoing provisions of this Section 6(b)). 

(c) Settlement of Claims. Brand Pharma shall not be liable to indemnify Indemnitee under this Agreement or otherwise for any amounts paid in
settlement of any Proceeding effected without Brand Pharma’s written consent, such consent not to be unreasonably withheld; provided, however, that if a Change in Control has occurred, Brand Pharma shall be liable for indemnification of
Indemnitee for amounts paid in settlement if the Independent Counsel has approved the settlement. Brand Pharma shall not settle any Proceeding in any manner that would impose any penalty or limitation on Indemnitee without Indemnitee’s written
consent. Brand Pharma shall not be liable to indemnify the Indemnitee under this Agreement with regard to any judicial award if Brand Pharma was not given a reasonable and timely opportunity, at its expense, to participate in the defense of such
action; Brand Pharma’s liability hereunder shall not be excused if assumption of the defense of the Proceeding by Brand Pharma was barred by this Agreement. 
 7. Establishment of Trust. In the event of a Change in Control Brand Pharma shall, upon written request by Indemnitee, create a trust for the benefit of the Indemnitee (the “Trust”) and
from time to time upon written request of Indemnitee shall fund the Trust in an amount sufficient to satisfy any and all Expenses reasonably anticipated at the time of each such request (a) to be incurred in connection with investigating,
preparing for, participating in, and/or defending any Proceeding relating to an Indemnifiable Event and (b) to be indemnifiable pursuant to this Agreement. The amount or amounts to be deposited in the Trust pursuant to the foregoing funding
obligation shall be determined by the Independent Counsel. The terms of the Trust shall provide that (i) the Trust shall not be revoked or the principal thereof invaded without the written consent of the Indemnitee, (ii) the Trustee (as
defined below) shall advance, within five business days of a request by the Indemnitee, any and all Expenses to the Indemnitee on the same terms and conditions as provided in Section 2(c) (and the Indemnitee hereby agrees to reimburse the Trust
under the same circumstances for which the Indemnitee would be required to reimburse Brand Pharma under Section 2(c) of this Agreement), (iii) the Trust shall continue to be funded by Brand Pharma in accordance with the funding obligation
set forth above, (iv) the Trustee shall promptly pay to the Indemnitee all amounts for which the Indemnitee shall be entitled to indemnification pursuant to this Agreement, and (v) all unexpended funds in the Trust shall revert to


  
 - 9 -









 
Brand Pharma upon a final determination by the Independent Counsel or a court of competent jurisdiction, as the case may be, that the Indemnitee has been fully indemnified under the terms of this
Agreement. The trustee of the Trust (the “Trustee”) shall be chosen by the Indemnitee. Nothing in this Section 7 shall relieve Brand Pharma of any of its obligations under this Agreement. All income earned on the assets held in the
Trust shall be reported as income by Brand Pharma for federal, state, local, and foreign tax purposes. Brand Pharma shall pay all costs of establishing and maintaining the Trust and shall indemnify the Trustee against any and all expenses (including
attorney’s fees), claims, liabilities, loss, and damages arising out of or relating to this Agreement or the establishment and maintenance of the Trust. 
 8. Non-Exclusivity. The rights of Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under Mallinckrodt plc’s Articles of Association, the separate deed of
indemnification which Indemnitee has with Mallinckrodt plc, the Brand Pharma Organizational Documents, applicable law or otherwise. To the extent that a change in applicable law (whether by statute or judicial decision) permits greater
indemnification than would be afforded currently under Mallinckrodt plc’s Articles of Association, the separate deed of indemnification which Indemnitee has with Mallinckrodt plc, the Brand Pharma Organizational Documents, applicable law or
this Agreement, it is the intent of the parties that Indemnitee enjoy by this Agreement the greater benefits so afforded by such change.
 9.
Continuation of Contractual Indemnity or Period of Limitations. All agreements and obligations of Brand Pharma contained herein shall continue for so long as Indemnitee shall be subject to, or involved in, any proceeding for which
indemnification is provided pursuant to this Agreement. Notwithstanding the foregoing, no legal action shall be brought and no cause of action shall be asserted by or on behalf of Brand Pharma or any Affiliate of Brand Pharma against Indemnitee,
Indemnitee’s spouse, heirs, executors, or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, or such longer period as may be required by the laws of Delaware under the
circumstances. Any claim or cause of action of Brand Pharma or its Affiliate shall be extinguished and deemed released unless asserted by the timely filing and notice of a legal action within such period; provided, however, that if any shorter
period of limitations is otherwise applicable to any such cause of action, the shorter period shall govern. 
 10. Contribution. To the
fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever (other than pursuant to the terms hereof), Brand Pharma, in lieu of indemnifying
Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an Indemnifiable Event
under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by Mallinckrodt plc and Brand Pharma, on one hand, and
Indemnitee, on the other hand, as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of Mallinckrodt plc and Brand Pharma (and their respective directors, officers, employees and
agents), on one hand, and Indemnitee, on the other hand, in connection with such event(s) and/or transaction(s).

  
 - 10 -









 11. Amendment of this Agreement. No supplement, modification, or amendment of this Agreement shall be
binding unless executed in writing by each of the parties hereto. No waiver of any of the provisions of this Agreement shall be binding unless in the form of a writing signed by the party against whom enforcement of the waiver is sought, and no such
waiver shall operate as a continuing waiver. Except as specifically provided herein, no failure to exercise or any delay in exercising any right or remedy hereunder shall constitute a waiver thereof.

12. Subrogation. In the event of payment under this Agreement, Brand Pharma shall be subrogated to the extent of such payment to all of the rights
of recovery of Indemnitee, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable Brand Pharma effectively to bring suit to enforce
such rights.
 13. No Duplication of Payments. Brand Pharma shall not be liable under this Agreement to make any payment in connection
with any claim made by Indemnitee to the extent Indemnitee has otherwise received payment (under any insurance policy, Mallinckrodt plc’s Articles of Association, the separate deed of indemnification which Indemnitee has with Mallinckrodt plc,
the Brand Pharma Organizational Documents or otherwise) of the amounts otherwise indemnifiable hereunder. 
 14. Binding Effect. This
Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation, or otherwise to all or substantially
all of the business and/or assets of the Brand Pharma), assigns, spouses, heirs, and personal and legal representatives. Brand Pharma shall require and cause any successor thereof (whether direct or indirect by purchase, merger, consolidation, or
otherwise) to all, substantially all, or a substantial part, of the business and/or assets of the Brand Pharma, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the
same manner and to the same extent that Brand Pharma would be required to perform if no such succession had taken place. The indemnification provided under this Agreement shall continue as to Indemnitee for any action taken or not taken while
serving in an indemnified capacity pertaining to an Indemnifiable Event even though he may have ceased to serve in such capacity at the time of any Proceeding or is deceased and shall inure to the benefit of the heirs, executors, administrators,
legatees and assigns of such a person.
 15. Severability. If any provision (or portion thereof) of this Agreement shall be held by a
court of competent jurisdiction to be invalid, void, or otherwise unenforceable, the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore, to the fullest extent possible, the provisions of this Agreement
(including, without limitation, each portion of this Agreement containing any provision held to be invalid, void, or otherwise unenforceable, that is not itself invalid, void or unenforceable) shall be construed so as to give effect to the intent
manifested by the provision held invalid, void or unenforceable.
 16. Governing Law. This Agreement shall be governed by and construed
and enforced in accordance with the laws of Delaware applicable to contracts made and to be performed in such State without giving effects to its principles of conflicts of laws.

  
 - 11 -









 17. Notices. All notices, demands, and other communications required or permitted hereunder shall be
made in writing and shall be deem to have been duly given if delivered by hand, against receipt, or mailed, postage prepaid, certified or registered mail, return receipt requested, and address to Brand Pharma at: 

Mallinckrodt Brand Pharmaceuticals, Inc. 
 675 James S. McDonnell Blvd. 
 Hazelwood, MO 63042 

Attn: Secretary 

Facsimile: 314-654-5366 
 If to
Mallinckrodt plc, to: 
 Mallinckrodt plc 
 Damastown 
 Mulhuddart 

Dublin 15 

Ireland 
 Attn:
General Counsel 
 Facsimile: +352-266-379-92 
 and 
 Mallinckrodt 

675 James S. McDonnell Blvd. 
 Hazelwood, MO 63042 
 Attn: General Counsel 

Facsimile: 314-654-5366 
 And to
Indemnitee at: 
 Notice of change of address shall be effective only when given in accordance with this Section. All notices complying with
this Section shall be deemed to have been received on the date of hand delivery or on the third business day after mailing. 
 18.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

  
 - 12 -









 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as
the day specified above. 
  

			
	 MALLINCKRODT BRAND PHARMACEUTICALS, INC.

 
  
  

 

	  

		
	 By:
	 	
	 Its:
	 	
	
	 INDEMNITEE

 
  
  

 

	  

	
	 Typed Name:



  
 - 13 -